Inflammation in schizophrenia: pathogenetic aspects and therapeutic considerations.
Open accessThe DOI matches its Crossref record; 128 of the 130 references it cites were found in a registry or an index.
Abstract
This paper discusses the current evidence from animal and human studies for a central role of inflammation in schizophrenia. In animal models, pre- or perinatal elicitation of the immune response may increase immune reactivity throughout life, and similar findings have been described in humans. Levels of pro-inflammatory markers, such as cytokines, have been found to be increased in the blood and cerebrospinal fluid of patients with schizophrenia. Numerous epidemiological and clinical studies have provided evidence that various infectious agents are risk factors for schizophrenia and other psychoses. For example, a large-scale epidemiological study performed in Denmark clearly showed that severe infections and autoimmune disorders are such risk factors. The vulnerability-stress-inflammation model may help to explain the role of inflammation in schizophrenia because stress can increase pro-inflammatory cytokines and may even contribute to a chronic pro-inflammatory state. Schizophrenia is characterized by risk genes that promote inflammation and by environmental stress factors and alterations of the immune system. Typical alterations of dopaminergic, serotonergic, noradrenergic, and glutamatergic neurotransmission described in schizophrenia have also been found in low-level neuroinflammation and consequently may be key factors in the generation of schizophrenia symptoms. Further support for the relevance of a low-level neuroinflammatory process in schizophrenia is provided by the loss of central nervous system volume and microglial activation demonstrated in neuroimaging studies. Last but not least, the benefit of anti-inflammatory medications found in some studies and the intrinsic anti-inflammatory and immunomodulatory effects of antipsychotics provide further support for the role of inflammation in this debilitating disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Evidence of altered inflammation-related markers across psychiatric conditions [6–8], along with reports of anti-inflammatory effects from psychotropic medications [9, 10] and the ameliorative impact of anti-inflammatory drugs on psychiatric symptoms [11–14], suggests a strong link between abnormal inflammatory responses and major psychiatric disorders.”
From Inflammatory ratios as predictors of length of hospitalization in psychiatric patients: A multicenter study (2025) · doi:10.1007/s00406-025-02033-9 · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A growing body of evidence suggests that immune dysfunction and inflammation have been considered to play important roles in the pathogenesis of SCZ and BD (11, 12).”
From Investigation of systemic immune-inflammation index, neutrophil/high-density lipoprotein ratio, lymphocyte/high-density lipoprotein ratio, and monocyte/high-density lipoprotein ratio as indicators of inflammation in patients with schizophrenia and bipolar disorder (2022) · cites this paper as [12]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Changes of some inflammation-related factors (IRFs) have been intensively studied and reviewed in relation to psychiatric disorders1–9.”
From Inflammation-related biomarkers in major psychiatric disorders: a cross-disorder assessment of reproducibility and specificity in 43 meta-analyses (2019) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“Recent evidence suggests the involvement of the immune system in several psychiatric conditions [203–205]; one of the most studied in this respect is depression [206–208].”
From Molecular Characterisation of the Mechanism of Action of Stimulant Drugs Lisdexamfetamine and Methylphenidate on ADHD Neurobiology: A Review (2022) · cites this paper as [203]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Murphy, K., & Weaver, C. (2016) · W.W. Norton eBooks · doi:10.1201/9781315533247 · Cited by 2,258
Vulnerability: A new view of schizophrenia.
Zubin, J., & Spring, B. (1977) · Journal of Abnormal Psychology · doi:10.1037/0021-843x.86.2.103 · Cited by 1,992
Cortical demyelination and diffuse white matter injury in multiple sclerosis
Kutzelnigg, A., Lucchinetti, C. F., Stadelmann, C., Brück, W., Rauschka, H., Bergmann, M., Schmidbauer, M., Parisi, J. E., & Lassmann, H. (2005) · Brain · doi:10.1093/brain/awh641 · Cited by 1,836
Goldsmith, D. R., Rapaport, M. H., & Miller, B. J. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.3 · Cited by 1,683
Raison, C. L., Rutherford, R. E., Woolwine, B. J., Shuo, C., Schettler, P., Drake, D. F., Haroon, E., & Miller, A. H. (2013) · JAMA Psychiatry · doi:10.1001/2013.jamapsychiatry.4 · Cited by 1,617
Maternal Immune Activation Alters Fetal Brain Development through Interleukin-6
Smith, S. E. P., Li, J., Garbett, K., Mirnics, K., & Patterson, P. H. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2178-07.2007 · Cited by 1,605
Serologic Evidence of Prenatal Influenza in the Etiology of Schizophrenia
Brown, A. S., Begg, M. D., Gravenstein, S., Schaefer, C. A., Wyatt, R. J., Bresnahan, M., Babulas, V. P., & Susser, E. S. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.8.774 · Cited by 1,053
The current status of the dopamine hypothesis of schizophrenia
CARLSSON, A. (1988) · Neuropsychopharmacology · doi:10.1016/0893-133x(88)90012-7 · Cited by 958
Neuropharmacology of quinolinic and kynurenic acids.
Stone, T. W. (1993) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00441-7 · Cited by 948
Cytokine-induced sickness behavior: where do we stand?
Dantzer, R. (2001) · Brain, Behavior, and Immunity · doi:10.1006/brbi.2000.0613 · Cited by 862
Cited by
Items 401–500 of 648
Queiroz, S. D. A., Júnior, L. R. D. N., de Carvalho, A. B. P., da Silva, T. V., Ramos, S. D. S., Meneguzzo, V., Mathias, K., Tiscoski, A. D. B., Piacentini, N., Goldim, M. P. D. S., et al. (2025) · Schizophrenia Research · doi:10.1016/j.schres.2025.03.031 · Cited by 3
Humble, M. B., Mobarrez, F., Eklund, D., Bejerot, S., & Wetterberg, L. (2025) · Schizophrenia Research · doi:10.1016/j.schres.2025.08.006 · Cited by 3
“An increasing body of evidence suggests that neuroinflammation and immune dysregulation play significant roles in the pathophysiology of schizophrenia (Müller, 2018), while the evidence for OCD seems confined to certain subtypes (Endres et al., 2022).”
Jovani, A., Moliner-Castellano, B., Gimeno-Vergara, R., Benito, A., Marí-Sanmillán, M. I., Castellano-García, F., & Haro, G. (2025) · World Journal of Psychiatry · doi:10.5498/wjp.v15.i9.108465 · Cited by 3
Alterations in the plasma concentrations of BDNF, proBDNF, and MMP-9 in patients with schizophrenia
Liang, Y., Pan, H., Yang, Z., Yu, C., Jiang, T., Li, Y., Yu, H., Qiu, M., & Zhang, S. (2025) · European journal of medical research · doi:10.1186/s40001-025-03153-7 · Cited by 5
“However, the lack of stage-specific biomarker differences between FE-SCZ and RE-SCZ contrasts with reports of progressive inflammatory escalation in chronic SCZ, possibly due to sample heterogeneity or cross-sectional design limitations [36].”
Коровайцева, Г. И., Габаева, М. В., Oleichik, I. V., & Голимбет, В. Е. (2021) · Russian Journal of Genetics · doi:10.1134/s102279542102006x · Cited by 3
Jansma, J., van Essen, R., Haarman, B. C. M., Chatziioannou, A. C., Borkent, J., Ioannou, M., van Hemert, S., Sommer, I. E., & Aidy, S. E. (2022) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2022.05.011 · Cited by 4
Yee, J. Y., Chow, S. Q., Lim, K., Goh, W. W. B., Sng, J., Lee, T.-S. W., & Lee, J. (2022) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2022.100481 · Cited by 3
“This is consistent with findings from other immune biomarker studies in psychosis and might indicate a low-grade inflammatory process or immune dysregulation, rather than an acute inflammatory process (Müller, 2018; Osimo et al., 2018; Fond et al., 2019).”
ResultMicroglial Reactivity in the Prefrontal Cortex in Schizophrenia with Different Types of Course
Vikhreva, O. V., & Uranova, N. A. (2022) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-022-01289-1 · Cited by 3
Uranova, N. A., Vikhreva, O. V., & Рахманова, В. И. (2022) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro2022122121128 · Cited by 4
Yang, K., Zeng, X., Li, H., Chen, J., Zhu, W., Wang, Y., & Zhao, X. (2023) · Concepts in Magnetic Resonance Part A · doi:10.1155/2023/8953242 · Cited by 3
Mueller, J. K., Ahrens, K. F., Bauer, M., Baune, B. T., Borgwardt, S., Deckert, J., Domschke, K., Ellwanger, R., Fallgatter, A. J., Frodl, T., et al. (2023) · Pharmacopsychiatry · doi:10.1055/a-2177-3056 · Cited by 4
bahnamiri, P. J., Moghaddam, A. H., Ranjbar, M., & Nazifi, E. (2023) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2023.101594 · Cited by 5
“Neuroimaging studies have confirmed the microglia activation in patients and animal models of SCZ [51].”
BackgroundHealy, C., Byrne, J. F., Susai, S. R., Föcking, M., Mongan, D., Kodosaki, E., Heurich, M., Cagney, G., Wynne, K. J., Bearden, C. E., et al. (2024) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2023.12.018 · Cited by 3
“It should be noted that the degree of dysregulation observed in the CHR samples was in line with low-level dysregulation, rather than severe inflammatory dysregulation as may occur in the context of acute infection or injury (Müller (2018)).”
Unique Challenges in Biomarkers for Psychotic Disorders
Chen, E. Y. H., & Wong, S. M. Y. (2024) · Brain Sciences · doi:10.3390/brainsci14010106 · Cited by 3
Perspective Chapter: Aspirin – The Wonder Drug
Ishola, A. A. (2024) · Pharmaceutical science. · doi:10.5772/intechopen.111571 · Cited by 4
Hemostasis System in Patients with Schizophrenia and Schizophrenia Spectrum Disorders
Karpova, N. S., Os, B., Oleichik, I. V., Stolyarov, S. A., & Klyushnik, T. P. (2024) · Bulletin of Experimental Biology and Medicine · doi:10.1007/s10517-024-06030-1 · Cited by 4
“According to modern concepts, the key pathogenetic element of endogenous mental disorders is neuroin-flammation associated with peripheral inflammation [1-4].”
Bastawy, E. M., Eraslan, I. M., Voglsanger, L. M., Suphioglu, C., Walker, A. J., Dean, O. M., Read, J. L., Ziemann, M., & Smith, C. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137391 · Cited by 4
Assessment of Innovative Pharmacological Targets in Schizophrenia
de Sousa, T. R., Ribeiro, M., & Novais, F. (2024) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-024-00324-x · Cited by 7
“Some PET studies have shown higher levels of microglia-mediated inflammation [94], especially in recent disease onset cases [95].”
InfluentialAsada, R., Hori, H., Gotoh, L., Yasumatsu, K., Iida, H., & Kawasaki, H. (2024) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2024.07.029 · Cited by 5
Sun, Y., Wu, D., Yang, X., Tang, B., Xia, C., Luo, C., Gong, Q., Lui, S., & Hu, N. (2024) · Cerebral Cortex · doi:10.1093/cercor/bhae308 · Cited by 3
Guo, X., Kong, L., Wen, Y., Chen, L., & Hu, S. (2024) · BMC Psychiatry · doi:10.1186/s12888-024-06141-z · Cited by 4
Cao, Y., Liang, J., Dai, B., Shan, F., & Xia, Q. (2024) · BMC Psychiatry · doi:10.1186/s12888-024-06437-0 · Cited by 4
Solutions for a Perplexing Conundrum: Immunologic Abnormalities in Schizophrenia
Nimgaonkar, V. L. (2018) · Schizophrenia Bulletin · doi:10.1093/schbul/sby099 · Cited by 3
Immunological and clinical aspects of the long-term stages of youth schizophrenia
Zozulya, S. A., Golubev, S. A., Tikhonov, D. V., Каледа, В. Г., & Klyushnik, T. P. (2022) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro20221220125 · Cited by 3
Yao, Y., Xu, Y., Guo, H., Han, K., & Dai, Z. (2022) · Computational and Mathematical Methods in Medicine · doi:10.1155/2022/1862396 · Cited by 3
“In recent years, influenced by the continuous improvement and development of the medical service model and the increasing requirements for the quality of clinical care put forward by modern people, the clinical treatment of schizophrenia groups has also received wide attention and importance from all walks of life [6].”
BackgroundRetractedD’Andrea, G., Pascale, R., Vatamanu, O., Giacomini, M., Caroccia, N., Giannella, M., Carloni, A. L., Cesa, F., Mordenti, O., Muratori, R., et al. (2023) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2023.111199 · Cited by 4
Atypical Antipsychotic Medications Disrupt the Cardio-Metabolic and Cardio-Immune Axes
Rostama, B., May, M. A., & Houseknecht, K. (2020) · Interventional Cardiology · doi:10.37532/fmic.2020.12(2).648 · Cited by 5
The functional activity of neutrophils in paranoid schizophrenia and Alzheimer’s disease
Proskurnina, E. V., Sokolova, S. V., Grishina, N. K., Sozarukova, M. M., Гайфуллин, Н., & Khannanova, A. N. (2020) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro202012004197 · Cited by 3
Александровна, О. В., Михайлова, И. И., Леонидович, М. В., Симонова, А. В., & Pogodina, E. A. (2020) · Doctor Ru · doi:10.31550/1727-2378-2020-19-4-43-49 · Cited by 3
Pujol, N., Bergé, D., Mané, A., Bioque, M., Mezquida, G., Amoretti, S., Baeza, I., González-Pinto, A., Lobo, A., Cuesta, M. J., et al. (2022) · Psychiatry Research · doi:10.1016/j.psychres.2022.114760 · Cited by 3
Chang, F., Chen, P.-A., Siao, W.-H., & Chen, Y.-C. (2023) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2023.103569 · Cited by 4
“This sensitization process may induce biological vulnerability to external stress and cause the episode of mental disorders (Muller, 2018).”
Hrivikova, K., Marko, M., Karailievova, L., Romanova, Z., Oravcová, H., Riečanský, I., & Ježová, D. (2023) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2023.106287 · Cited by 3
Siafakas, N., Anastassopoulou, C. G., Pournaras, S., Tsakris, A., Alevizakis, E., Kympouropoulos, S. P., Spandidos, D. A., & Rizos, E. N. (2024) · Molecular Medicine Reports · doi:10.3892/mmr.2024.13426 · Cited by 2
“…c‑reactive protein in both childhood and adolescence have been shown to be linked to both the presence and severity of disease during adulthood (37,38). il‑6 is also considered not only as an important, diagnostic inflammatory marker but as a predictive one as well, since its increased levels…”
Aging in Schizophrenia: Perspectives on Molecular Mechanisms and a Mini-review
Weerasekera, A., Dost, Ö., & Fei, D. (2025) · Schizophrenia Bulletin · doi:10.1093/schbul/sbaf099 · Cited by 2
Kancsev, A., Engh, M. A., Horváth, A., Hegyi, P., Kelemen, O., & Kéri, S. (2025) · Schizophrenia · doi:10.1038/s41537-025-00694-y · Cited by 3
Brain Extracellular Space: From an Overlooked Dimension to Catalyst of a Novel Neuroscience Paradigm
Han, H., Dai, H., Lopes, L. S., Ni, R., Combes, B. F., Song, Y., Tan, H., Xu, M., Li, H., Lv, S., et al. (2026) · Cyborg and Bionic Systems · doi:10.34133/cbsystems.0529 · Cited by 3
“The pathophysiological mechanisms of schizophrenia (SCZ) remain incompletely elucidated, with mainstream hypotheses focusing on neural circuit dysfunction (dopaminergic hyper-activation and glutamatergic hypoactivity), synaptic dysfunction, and chronic neuroinflammation [ 172 – 176 ].”
Saha, T., Vats, T., & Mehan, S. (2026) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2026.2671714 · Cited by 2
“An increased risk of schizophrenia in [261] adulthood is associated with higher inflammatory markers during childhood or adolescence, and people with schizophrenia exhibit elevated levels of pro-inflammatory cytokines compared to healthy controls [262]. there are numerous reports of increased…”
Schizophrenia: Presentation, Affect and Cognition, Pathophysiology and Etiology
MacDonald, A. W., & Demro, C. (2023) · Oxford University Press eBooks · doi:10.1093/med-psych/9780197542521.003.0014 · Cited by 2
Roméo, B., Mazari, A., Ali-Diabacte, H., Lestra, V., Martelli, C., Benyamina, A., & Hamdani, N. (2023) · L Encéphale · doi:10.1016/j.encep.2023.02.001 · Cited by 2
Crump, C., Good, M. E., Abuelazm, H., & El‐Mallakh, R. S. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2208269 · Cited by 4
“2020; Müller 2018) [49,50], as demonstrated by the successful use of anti-inflammatory agents in adults with schizophrenia (Zheng et al.”
BackgroundSikorski, P., Sikorska, E., Michalska, M. N., Stec, A., Kasarełło, K., & Fudalej, S. (2023) · Current Problems of Psychiatry · doi:10.12923/2353-8627/2023-0010 · Cited by 3
Taskiran, S. Y., Taşkıran, M., Ünal, G., Bozkurt, N. M., & Gölgeli, A. (2023) · Behavioural Brain Research · doi:10.1016/j.bbr.2023.114565 · Cited by 3
Yazarlou, F., Tabibian, M., Azarnezhad, A., Sadeghirad, H., Lipovich, L., Sanati, G., Abdolmaleky, H. M., & Alizadeh, F. (2023) · Journal of Molecular Neuroscience · doi:10.1007/s12031-023-02150-x · Cited by 3
“Moreover, SCZ can affect the whole body systematically; for instance, inflammation is reportedly a part of the observed pathophysiology (Müller 2018).”
BackgroundRoméo, B., Lestra, V., Martelli, C., Amirouche, A., Benyamina, A., & Hamdani, N. (2023) · Pathogens · doi:10.3390/pathogens12111333 · Cited by 2
Rittmannsberger, H., Barth, M., Lamprecht, B., Malík, P., & Yazdi‐Zorn, K. (2023) · Neuropsychiatrie · doi:10.1007/s40211-023-00487-8 · Cited by 2
Functional foods and neuroinflammation: Focus on autism spectrum disorder and schizophrenia
Matrisciano, F. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-91747-6.00012-3 · Cited by 2
Kozlov, V. A., Голенков, А. В., Zotov, P. B., & Евгеньевна, Б. И. (2024) · Суицидология · doi:10.32878/suiciderus.24-15-01(54)-3-30 · Cited by 2
Sun, X., Li, M., Qiu, Y., Su, Q., Wang, J., Bi, F., & Li, J. (2024) · Schizophrenia Research · doi:10.1016/j.schres.2024.10.025 · Cited by 3
Müller, N. (2024) · NeuroImmunoModulation · doi:10.1159/000542784 · Cited by 4
Self-citationDynamic Real‐Time Biosensing Enabled Biorhythm Tracking for Psychiatric Disorders
Huizer, K., Banga, I. K., Kumar, R. M., Muthukumar, S., & Prasad, S. (2024) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.2021 · Cited by 2
Liu, D., Zhu, C., & Wei, H. P. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110286 · Cited by 4
Muduli, A., Satapathy, B. S., Pattnaik, S., & Maharana, L. (2025) · Current Nanomaterials · doi:10.2174/0124054615358881250131070918 · Cited by 2
An Integrative and Mechanistic Model of Impaired Belief Updating in Schizophrenia
Ghane, M., & Sparer, T. (2019) · Journal of Neuroscience · doi:10.1523/jneurosci.0002-19.2019 · Cited by 2
“However, the degree to which noise in prefrontal regions correlates with specific symptom domains may depend on context-dependent changes in neuromodulatory activity in other cortical/subcortical regions (e.g., because of chronic/acute stress, environmental changes, or medication; Keedy et al., 2009; Stephan and Mathy…”
BackgroundVenkatasubramanian, G., Shivakumar, V., Sreeraj, V. S., Subbanna, M., Kalmady, S. V., Amaresha, A. C., Narayanaswamy, J., & Debnath, M. (2020) · Indian Journal of Psychiatry · doi:10.4103/psychiatry.indianjpsychiatry_486_19 · Cited by 2
“[43] This could either be a result of greater physiological and psychological stressors during the neurodevelopmental period[44] and/ or an oversensitive neuro-inflammatory response.[45] The GC genotype could mitigate the IL-6 response in SCZ and protect the hippocampus during developmental age.”
BackgroundThe polymorphism of TNFα (rs1799964) gene and schizophrenia risk: A meta-analysis
Moossavi, M., Alaei, M., Mohammadoo-khorasani, M., Shojaee, M., & Khorasani, M. (2020) · Meta Gene · doi:10.1016/j.mgene.2020.100801 · Cited by 2
Physiology and miRNA expression in confined sows with different pupillary light reflex
Wang, L., Yu, L., & Yin, G. (2021) · Italian Journal of Animal Science · doi:10.1080/1828051x.2021.1895680 · Cited by 2
“Studies have shown that immune inflammatory responses can induce schizophrenia and bipolar disorder (Lutz and Kieffer 2013; Muller 2018).”
BackgroundInfluentialCOVID-19-Impfung unter Psychopharmakotherapie
Seifert, J., Heck, J., Eckermann, G., Singer, M., Bleich, S., Grohmann, R., & Toto, S. (2021) · Psychiatrische Praxis · doi:10.1055/a-1531-4460 · Cited by 2
Vasilyeva, E. F., Sekirina, T. P., Omelchenko, M. A., Sarmanova, Z. V., Faktor, M. I., & Brusov, O. S. (2021) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro202112111161 · Cited by 2
Dysfunctional oxidative stress response in first-episode of schizophrenia
Zhai, X., Kang, Y., Yuan, X., Wang, Y., Lu, S., & Lu, Z. (2022) · Tropical Journal of Pharmaceutical Research · doi:10.4314/tjpr.v20i6.22 · Cited by 2
DNA Hyper-methylation Associated With Schizophrenia May Lead to Increased Levels of Autoantibodies
Wei, H., Yuan, Y., Zhu, C., Ma, M., Yang, F., Lu, Z., Wang, C., Deng, H., Zhao, J., Tian, R., et al. (2022) · Schizophrenia Bulletin Open · doi:10.1093/schizbullopen/sgac047 · Cited by 2
“40,41 Antipsychotic medications can also reduce disease severity, inflammatory cytokines, and autoantibody levels in autoimmune encephalomye-litis, which has overlapped clinical symptoms with SCZ.”
BackgroundQuality assessment of Rheum species cultivated in Japan by focusing on M2 polarization of microglia
Kuboyama, T., Hotta, K., Asanuma, M., Ge, Y., Toume, K., Yamazaki, T., & Komatsu, K. (2023) · Journal of Natural Medicines · doi:10.1007/s11418-023-01710-0 · Cited by 2
“Inflammation is considered a major cause of psychiatric diseases such as depression and schizophrenia [35, 36].”
BackgroundMicroglia-neuron interactions in the caudate nucleus in different course of schizophrenia
Vikhreva, O. V., Рахманова, В. И., & Uranova, N. A. (2024) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro2024124071154 · Cited by 2
Toriumi, K., Berto, S., Koike, S., Usui, N., Dan, T., Suzuki, K., Miyashita, M., Horiuchi, Y., Yoshikawa, A., Sugaya, Y., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.08.192906 · Cited by 2
Sánchez‐Ramón, S., Faure, F., Jolles, S. R. A., Leboyer, M., & Tremblay, M. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.733997 · Cited by 2
“Environmental inflammatory insults early in life and altered social behaviors have long been recognized to trigger the development of the disease (Zubin and Spring, 1977; Müller, 2018).”
Background(2025) · doi:10.1007/s00406-025-02033-9 · Cited by 1
Immune factors associated with prominent negative symptoms and disease severity in schizophrenia
Малашенкова, И. К., Krynskiy, S., Ogurtsov, D., Hailov, N. A., Ratushnyy, A. Y., Filippova, E. A., Melnikova, V. D., Kaydan, M. A., Kostyuk, G. P., & Didkovsky, N. A. (2024) · Russian Journal of Immunology · doi:10.46235/1028-7221-16931-ifa · Cited by 1
Qin, F., Xiang, C., Xinling, Z., Zeyi, G., Liu, Y., Wen, J., Qing, L., Zhaowei, T., & Yong, Z. (2024) · BMC Psychiatry · doi:10.1186/s12888-024-06100-8 · Cited by 4
“…by early life adversities such as perinatal infections, maltreatment or bullying, and sub-stance-related factors such as drugs and alcohol [34–36], one of the major strengths of the Mendelian randomization approach, as opposed to observational studies where it is difficult to accurately…”
BackgroundExpression pattern of long non-coding RNAs in treatment-naïve and medicated schizophrenia patients
Javidi-Aghdam, K., Baradaran, B., Rahmani, S., Manafzadeh, F., Azar, S. G. N., Aghayan, S. S., Shayannia, A., & Ghafouri‐Fard, S. (2024) · Scientific Reports · doi:10.1038/s41598-024-78220-w · Cited by 1
“One of the important pathways involved in the development of schizophrenia is the inflammatory pathway 26 .”
Rodrigues, T., Bressan, G. N., Juliani, P. Z., da Silva, M. E. B., & Fachinetto, R. (2024) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2024.173950 · Cited by 2
Immunoinflammatory Mechanisms in Sex-Dependent Vulnerability to Neuropsychiatric Disorders
Macêdo, D. S., Torres, D., Gomes, N. S., Soares, M. V. R., Lós, D. B., & Fiorenza, N. G. (2024) · Integrated science · doi:10.1007/978-3-031-72079-6_4 · Cited by 1
Deng, M.-G., Chai, C., Wang, K., Zhao, Z.-H., Nie, J., Liu, F., Liang, Y.-H., & Liu, J.-W. (2025) · Progress in Neuro-psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111277 · Cited by 1
Dagnaw, G. G., Paltiel, O., & Shafrir, A. (2025) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-025-02860-0 · Cited by 1
“In addition, imbalanced T-cell responses [ 27 , 28], and inflammatory cytokine signalling disruptions are consistently observed in schizophrenia patients [ 29 ], which could contribute to severe COVID-19 outcomes.”
Cytomegalovirus: An undervalued biological parameter of cognition in schizophrenia
You, Z., Wang, L., Chen, S., Zou, L., & Tang, J. (2025) · Brain Research · doi:10.1016/j.brainres.2025.149719 · Cited by 2
Evaluation of Calprotectin and Other İnflammatory Parameters in Patients with Schizophrenia
Erdal, H., Ayhan, M. G., & İnanlı, İ. (2025) · Bratislavské lekárske listy/Bratislava medical journal · doi:10.1007/s44411-025-00235-0 · Cited by 3
“While the dopamine hypothesis has long been the dominant neurobiological model of schizophrenia, increasing evidence suggests that immune system dysregulation, particularly inflammation, plays a crucial role in the pathophysiology of the disorder [2].”
Xiao, J., & Severance, E. G. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106313 · Cited by 1
Vikhreva, O. V., Рахманова, В. И., & Uranova, N. A. (2025) · Psikhiatriya · doi:10.30629/2618-6667-2025-23-3-42-53 · Cited by 1
Interleukin-5, Eosinophil, and Immunoglobulin A Levels in Schizophrenia Patients
Li, X., Wang, X., Zhou, Q., Zhang, Q., & Pan, S. (2025) · ALPHA PSYCHIATRY · doi:10.31083/ap46059 · Cited by 1
Meena, R., Meena, R., & Meena, J. S. (2025) · Cureus · doi:10.7759/cureus.93204 · Cited by 1
“Its etiology involves genetic predisposition, environmental triggers, neurotransmitter dysregulation, and immune dysfunction [2].”
Datta, A., Rana, H., Singh, S., & Singh, T. G. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111535 · Cited by 3
Lee, J.-Y., Liu, Y.-H., Hsieh, C. L., & Lung, F. (2025) · Science Progress · doi:10.1177/00368504251405328 · Cited by 1
Jeannin, J., Romeo, B. G. P., Lestra, V., Martelli, C., Amirouche, A., Benyamina, A., & Hamdani, N. (2026) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2026.02.041 · Cited by 2
Heterogeneity of schizophrenia through a peripheral inflammation lens: A mini-review
Zhang, R., Ren, J., & Zhang, C. (2026) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2026.106549 · Cited by 1
Dysregulation of the type I interferon signaling pathway in schizophrenia: A meta-analysis
Xie, M., Li, N., Ren, H., Zhang, X., Li, H., Mao, S., Wei, Z., Li, X., & Yu, Q. (2026) · Cytokine · doi:10.1016/j.cyto.2026.157146 · Cited by 1
Wu, J., Li, D., Mei, H., & Hu, Y. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.117949 · Cited by 1
Assessment of serum inflammatory cytokines in first-episode psychosis: Cross-sectional study
Qwabe, N., Paruk, S., Tomita, A. M., Karim, E., Chhagan, U., Ntlantsana, V., Chiliza, B., Abbai, N. S., Dessai, F., & Thela, L. T. (2026) · South African Journal of Psychiatry · doi:10.4102/sajpsychiatry.v32i0.2598 · Cited by 1
“…levels of serum cytokines may not reflect neuroinflammation occurring centrally in the brain, which is a key site of pathology in schizophrenia 9,57,58 Secondly, previous meta-analyses have highlighted methodological limitations across cytokine studies, including heterogeneous participant…”
Zheng, Y., Yuan, H., Gao, H., Jiang, J., & Zhu, Q. (2026) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-026-02272-4 · Cited by 1
From weather to symptoms: Preliminary links between weather and inflammation in schizophrenia
Modzelewski, S., Suprunowicz, M., Oracz, A. J., Marecki, R., Kosidło, J. W., Kamińska, J., Koper‐Lenkiewicz, O. M., Matowicka-Karna, J., & Waszkiewicz, N. (2026) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2026.101263 · Cited by 1
“Within this model, shifts in immune regulation (including T helper 1 (Th1) lymphocyte/T helper 2 (Th2) lymphocyte balance) (Budu-Aggrey et al., 2021; Fisman, 2012; Müller, 2018) are expected to translate weather exposure into changes in symptom severity (Waszkiewicz, 2023).”
Škutová, K., Fišar, Z., & Hroudová, J. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111749 · Cited by 2
Wang, Z., Shi, H., Guan, C., Li, X.-M., & Xu, H. Y. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1836674 · Cited by 1
Cavaleri, D., Crocamo, C., Cucchi, G., Bartoli, F., & Carrà, G. (2026) · Schizophrenia Research · doi:10.1016/j.schres.2026.06.015 · Cited by 1
Animal Models for Drug Discovery in Schizophrenia: A Critical View from a Clinical Perspective
Dammann-Bawadkji, I., Leweke, F. M., & Rohleder, C. (2026) · Pharmaceutical Medicine · doi:10.1007/s40290-026-00617-x · Cited by 1
Neuropsychiatric disorders and gut dysbiosis: what is the real impact of the kynurenine pathway?
Reyes-Martínez, S., del Campo, C. M. Z.-M., Tesoro-Cruz, E., Baldi, S., Aguirre‐García, M. M., & Amedei, A. (2026) · Neuroscience · doi:10.1016/j.neuroscience.2026.08.001 · Cited by 2
Kaga, I., Iwata, H., Tokushige, A., Akata, T., & Ueda, S. (2022) · Psychiatry and Clinical Neurosciences Reports · doi:10.1002/pcn5.25 · Cited by 1
“Enhanced inflammation, which is reportedly relevant to the pathogenesis of psychiatric diseases, 29,30 might adversely affect BMD. 31 However, there was no association between any markers for inflammation and BMD in the present study.”
BackgroundBrewer‐Smyth, K. (2022) · Springer eBooks · doi:10.1007/978-3-031-08801-8_12 · Cited by 3
PSYCHOLOGICAL DISTRESS AND COVID-19 INFECTION PERSPECTIVE
Shaw, R. B. (2022) · Psych-Talk · doi:10.53841/bpstalk.2022.1.101.23 · Cited by 1
Demir, F. Ü., Özsoy, F., & Aslan, E. A. (2023) · Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi · doi:10.17517/ksutfd.1127281 · Cited by 2
Talpur, M. A. R., Elsayed, O. H., & El‐Mallakh, R. S. (2023) · The University of Louisville Journal of Respiratory Infections · doi:10.55504/2473-2869.1268 · Cited by 1
“IL-6 is specifically linked to both the presence and the severity of the disease.[16, 55] C-reactive protein (CRP) and IL-6 in the childhood and adolescence periods are associated with schizophrenia.”
BackgroundInfluentialInnovation in psychopharmacology
Serretti, A. (2023) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000493 · Cited by 1
Голимбет, В. Е., & Klyushnik, T. P. (2023) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-023-01473-x · Cited by 1
Schizophrenia and Other Primary Psychotic Disorders
Lawrence, R. E., Becker, I., & McGorry, P. D. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_104-1 · Cited by 3
Metadata
- Authors
- Müller, N.
- Affiliations
- Ludwig-Maximilians-Universität München (DE)
- Corresponding author
- Müller, Norbert
- ORCID
- Müller, Norbert
- Venue
- Schizophrenia Bulletin
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-04-10
- Volume
- 44
- Issue
- 5
- Pages
- 973-982
- ISSN
- 0586-7614 (ISSN-L)
- 1745-1701
- PMC
- PMC6101562
- OpenAlex
- W2888647009
- Cited by
- 648
- References
- 130
- Citations by year
- 2026: 62 · 2025: 88 · 2024: 92 · 2023: 116 · 2022: 102 · 2021: 98 · 2020: 62 · 2019: 18 · 2018: 9
- FWCI
- 4.08
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Schizophrenia Bulletin (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- schizophrenia, neuroinflammation
- MeSH terms
- Animals, Anti-Inflammatory Agents, Humans, Inflammation, Schizophrenia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.